- Trials with a EudraCT protocol (609)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
609 result(s) found for: Blood pH.
Displaying page 5 of 31.
| EudraCT Number: 2017-003113-26 | Sponsor Protocol Number: CoLeBu | Start Date*: 2018-05-09 | |||||||||||
| Sponsor Name:ROSA HERRERA CASTRO | |||||||||||||
| Full Title: Hemodynamic safety of isobaric levobupivacaine versus isobaric bupivacaine for spinal anesthesia in patients over 65 years, underwent hip surgery. | |||||||||||||
| Medical condition: In patients 65 years or older undergoing hip surgery. | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-000602-17 | Sponsor Protocol Number: CABL001A2001B | Start Date*: 2021-08-10 | |||||||||||
| Sponsor Name:Novartis Pharma AG | |||||||||||||
| Full Title: An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit fr... | |||||||||||||
| Medical condition: CML-CP (at the end of parent study) who are currently participating in an asciminb Novartis sponsored study (parent study) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) DE (Ongoing) BG (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-004887-74 | Sponsor Protocol Number: AC-065D301 | Start Date*: 2019-08-14 | |||||||||||
| Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
| Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants with Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. | |||||||||||||
| Medical condition: sarcoidosis-associated pulmonary hypertension (SAPH) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed) HU (Prematurely Ended) PL (Completed) ES (Ongoing) BE (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-003520-10 | Sponsor Protocol Number: BAY63-2521/12166 | Start Date*: 2006-10-20 | |||||||||||
| Sponsor Name:Bayer HealthCare AG | |||||||||||||
| Full Title: A multicenter, non-randomized, non-blinded, non-controlled study to investigate the impact of multiple doses of BAY 63 2521 on safety, tolerability, pharmacokinetics, and pharmacodynamics in patien... | |||||||||||||
| Medical condition: Subjects with PH due to • Pulmonary arterial hypertension (PAH) [Venice protocol] or • Chronic thrombembolic PH (CTEPH) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-001286-15 | Sponsor Protocol Number: CGX-635-CML-203 | Start Date*: 2007-09-05 | |||||||||||
| Sponsor Name:Stragen France | |||||||||||||
| Full Title: A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) who have failed or are intolerant to t... | |||||||||||||
| Medical condition: Chronic Myeloid Leukaemia (CML) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) FR (Completed) GB (Completed) DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-002517-36 | Sponsor Protocol Number: CA180-015 | Start Date*: 2004-12-27 |
| Sponsor Name:Bristol Myers Squibb International Corporation | ||
| Full Title: A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib... | ||
| Medical condition: Lympohid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) AT (Completed) FI (Completed) GB (Completed) DK (Completed) IT (Completed) DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-002476-92 | Sponsor Protocol Number: 20120215 | Start Date*: 2015-06-29 | |||||||||||||||||||||
| Sponsor Name:Amgen Inc | |||||||||||||||||||||||
| Full Title: A Randomized, Open-label, Controlled Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidatio... | |||||||||||||||||||||||
| Medical condition: Patients with Philadelphia chromosome negative (Ph-) high-risk (HR) first relapse B-precursor ALL (as defined by I-BFM SG/IntReALL criteria) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Completed) CZ (Completed) BE (Completed) IT (Completed) SE (Completed) PT (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Ongoing) FR (Completed) NL (Completed) Outside EU/EEA GR (Completed) NO (Completed) HU (Completed) RO (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2018-003284-62 | Sponsor Protocol Number: 012508 | Start Date*: 2019-07-18 |
| Sponsor Name:Queen Mary University London | ||
| Full Title: A randomised, blinded, placebo controlled, Phase 2a study to evaluate the safety and efficacy of administering Regadenoson to patients with critical injury and signs of haemorrhagic shock | ||
| Medical condition: Cardiovascular collapse following traumatic haemorrhage | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-002726-20 | Sponsor Protocol Number: C-08-32 | Start Date*: 2017-11-07 | |||||||||||
| Sponsor Name:Alcon Research Ltd | |||||||||||||
| Full Title: Safety of PATANASE® Nasal Spray in Patients With Perennial Allergic Rhinitis | |||||||||||||
| Medical condition: Perennial Allergic Rhinitis | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-014774-18 | Sponsor Protocol Number: 09063 | Start Date*: 2009-10-29 |
| Sponsor Name:University of Nottingham | ||
| Full Title: The effects of balanced and unbalanced crystalloids and colloids on serum biochemistry and visceral blood flow: A two-phase, double-blind, randomised cross-over study | ||
| Medical condition: This is a healthy volunteer study investigating the effect of balanced and unbalanced fluid infusions on serum electrolytes, osmolality and acid/base balance. In addition we are examining the role ... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-005416-26 | Sponsor Protocol Number: ANSWER | Start Date*: 2014-06-06 |
| Sponsor Name:Mario Negri Institute | ||
| Full Title: A Prospective, Randomized, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess The Renal and Humoral Effects of Sevelamer Carbonate in Patients with Chronic Kidney Disease and Residual Protein... | ||
| Medical condition: Chronic Kidney Disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-001863-35 | Sponsor Protocol Number: THAM | Start Date*: 2016-06-21 |
| Sponsor Name:Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien | ||
| Full Title: Effects of Tromethamine on Cerebral Oxygenation and Metabolism in Patients Suffering Intractable Intracranial Hypertension – an exploratory study. | ||
| Medical condition: Critically ill patients (SAH, ICB, AVM bleedings, malignant MCA infarcts) under sedation and mechanical ventilation in need of multimodality monitoring, including brain tissue oxygen monitoring and... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-002942-30 | Sponsor Protocol Number: 01012015 | Start Date*: 2015-12-10 | ||||||||||||||||
| Sponsor Name:Regional Hospital of Randers | ||||||||||||||||||
| Full Title: CONDISOX: Continued versus discontinued oxytocin stimulation of labour in a double-blind randomised controlled trial | ||||||||||||||||||
| Medical condition: Syntocinon is used for labour induction to stimulate contractions. The current recommendation is to stimulate until delivery. We hypothesize that discontinuation of Syntocinon when the active phase... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Female | |||||||||||||||||
| Trial protocol: DK (Completed) NL (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2010-024332-42 | Sponsor Protocol Number: BAY63-2521/13605 | Start Date*: 2014-04-10 | |||||||||||
| Sponsor Name:Bayer HealthCare AG | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmon... | |||||||||||||
| Medical condition: pulmonary hypertension associated with idiopathic interstitial pneumonias | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) BE (Completed) GB (Completed) PT (Completed) DK (Completed) GR (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002916-34 | Sponsor Protocol Number: ITCC-054/AAML1921 | Start Date*: 2016-06-13 | |||||||||||
| Sponsor Name:Erasmus MC | |||||||||||||
| Full Title: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921 | |||||||||||||
| Medical condition: Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Trial now transitioned) IE (Completed) DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) DK (Completed) CZ (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-001318-92 | Sponsor Protocol Number: AP24534-15-303 | Start Date*: 2015-11-03 | |||||||||||
| Sponsor Name:ARIAD Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib | |||||||||||||
| Medical condition: Chronic Phase Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) DK (Prematurely Ended) CZ (Completed) PT (Completed) FR (Completed) AT (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-000158-36 | Sponsor Protocol Number: OXYPEP202 | Start Date*: 2016-03-18 | |||||||||||
| Sponsor Name:PEPTONIC medical AB | |||||||||||||
| Full Title: A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy | |||||||||||||
| Medical condition: Vaginal Atrophy | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: SE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-003737-26 | Sponsor Protocol Number: A3191342 | Start Date*: 2015-04-07 |
| Sponsor Name:Pfizer Inc | ||
| Full Title: A Phase 4, 6-week, randomized double-blind, multicenter, active-controlled trial to evaluate the effects of Celecoxib (Celebrex®) or Naproxen on blood pressure in paediatric subjects with juvenile ... | ||
| Medical condition: Juvenile idiopathic arthritis | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2011-002787-25 | Sponsor Protocol Number: GIMEMACML0811 | Start Date*: 2011-09-21 | |||||||||||
| Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO | |||||||||||||
| Full Title: The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+, BCR-ABL+ chronic myeloid leukemia (CML) in early chronic phase: a phase IIIb, multicenter study of complete molecular... | |||||||||||||
| Medical condition: Ph+, BCR-ABL+ chronic myeloid leukemia (CML) in early chronic phase | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-004251-23 | Sponsor Protocol Number: LAL2317 | Start Date*: 2018-04-26 | |||||||||||
| Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | |||||||||||||
| Full Title: National Treatment Program with Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Philadelphia Chromosome-Negative B-Cell | |||||||||||||
| Medical condition: Acute Lymphoblastic Leukemia Philadelphia Chromosome Negative (Ph-) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.